Analysts at RBC Capital Markets are out with a report this morning upgrading shares of eHealth, Inc. (EHTH) with an ‘Outperform‘ from ‘Sector Perform‘ rating. The firm raised its price target for the company to $16 from $14.
eHealth Inc. shares have a forward P/E of 450.67 and t-12 price-to-sales ratio of 1.14. EPS for the same period is ($0.93).
In the past 52 weeks, shares of Mountain View, California-based online health insurance services provider have traded between a low of $8.81 and a high of $37.87 and are now at $13.34. Shares are down 67.60% year-over-year and 51.40% year-to-date.
Analysts at Mizuho upgraded their rating on the shares of The Medicines Company (MDCO). In a research note published on Monday, the firm lifted the name with a ‘Buy‘ from ‘Neutral‘ rating and set a 12-month base case estimate of $41 from $28 per share.
On valuation measures, Medicines Co. shares have a t-12 price-to-sales ratio of 3.03. EPS is ($0.34). Currently there are 5 analysts that rate MDCO a ‘Buy‘, 5 rate it a ‘Hold‘. No analyst rates it a ‘Sell‘. MDCO has a median Wall Street price target of $32.00 with a high target of $42.00.
United Continental Holdings, Inc. (UAL) was raised to ‘Buy‘ from ‘Fair Value‘ at CRT Capital on Monday.
UAL is currently up $1.75 at $53.25 on normal volume. Midway through trading Monday, 3.22 million shares of United Continental Holdings Inc. have exchanged hands as compared to its average daily volume of 6.30 million shares. The stock has ranged in a price between $52.05 to $53.85 after having opened the day at $52.05 as compared to the previous trading day’s close of $51.50.
In the past 52 weeks, shares of Chicago, Illinois-based company have traded between a low of $36.65 and a high of $74.52. Shares are up 31.14% year-over-year ; down 23.01% year-to-date.
In a report published Monday, H.C. Wainwright analysts initiated coverage on Second Sight Medical Products, Inc. (EYES) with a ‘Buy‘ rating and $21 price target.
EYES shares recently gained $0.01 to $14.06. In the past 52 weeks, shares of Sylmar, California-based company have traded between a low of $8.05 and a high of $24.02. Shares are up 36.94% this year.
Eagle Pharmaceuticals Inc. (EGRX) was reiterated an ‘Overweight’ by Piper Jaffray analysts on Monday. The broker also raised its price target on the stock to $94 from $75.
EGRX is currently printing a higher than average trading volume with the issue trading 306K shares, compared to the average volume of 395K. The stock began trading this morning at $74.11 to currently trade 7.46% higher from the prior days close of $74.76. On an intraday basis it has gotten as low as $72.55 and as high as $81.60.
Eagle Pharmaceuticals is currently valued at $1.25 billion. The Woodcliff Lake, New Jersey-based company has a median Wall Street price target of $90.50 with a high target of $97.00. Eagle Pharmaceuticals Inc. is up 424.63% year-over-year, compared with a 5.01% gain in the S&P 500.